171 related articles for article (PubMed ID: 20096140)
1. Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer.
Kim SK; Kim EJ; Leem SH; Ha YS; Kim YJ; Kim WJ
BMC Cancer; 2010 Jan; 10():21. PubMed ID: 20096140
[TBL] [Abstract][Full Text] [Related]
2. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
3. mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer.
Ha YS; Kim MJ; Yoon HY; Kang HW; Kim YJ; Yun SJ; Lee SC; Kim WJ
Korean J Urol; 2010 Jan; 51(1):15-20. PubMed ID: 20414404
[TBL] [Abstract][Full Text] [Related]
4. A four-gene signature predicts disease progression in muscle invasive bladder cancer.
Kim WJ; Kim SK; Jeong P; Yun SJ; Cho IC; Kim IY; Moon SK; Um HD; Choi YH
Mol Med; 2011; 17(5-6):478-85. PubMed ID: 21308147
[TBL] [Abstract][Full Text] [Related]
5. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
7. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.
Kim WJ; Kim EJ; Kim SK; Kim YJ; Ha YS; Jeong P; Kim MJ; Yun SJ; Lee KM; Moon SK; Lee SC; Cha EJ; Bae SC
Mol Cancer; 2010 Jan; 9():3. PubMed ID: 20059769
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer.
Song BN; Kim SK; Chu IS
Exp Mol Med; 2017 Jan; 49(1):e282. PubMed ID: 28082741
[TBL] [Abstract][Full Text] [Related]
11. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.
Lee JS; Leem SH; Lee SY; Kim SC; Park ES; Kim SB; Kim SK; Kim YJ; Kim WJ; Chu IS
J Clin Oncol; 2010 Jun; 28(16):2660-7. PubMed ID: 20421545
[TBL] [Abstract][Full Text] [Related]
12. Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.
Yin H; Zhang C; Gou X; He W; Gan D
Oncol Rep; 2020 Feb; 43(2):379-394. PubMed ID: 31894276
[TBL] [Abstract][Full Text] [Related]
13. High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer.
Jiang S; Tian F; Wang Q; Cheng W; Wang L; Wang Y; Sun W
Cancer Biomark; 2018; 22(3):543-549. PubMed ID: 29865039
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
[TBL] [Abstract][Full Text] [Related]
15. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
16. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Yun SJ; Jo SW; Ha YS; Lee OJ; Kim WT; Kim YJ; Lee SC; Kim WJ
Urol Oncol; 2012; 30(6):893-9. PubMed ID: 21396842
[TBL] [Abstract][Full Text] [Related]
17. Three-gene signature predicts disease progression of non-muscle invasive bladder cancer.
Jeong P; Ha YS; Cho IC; Yun SJ; Yoo ES; Kim IY; Choi YH; Moon SK; Kim WJ
Oncol Lett; 2011 Jul; 2(4):679-684. PubMed ID: 22848249
[TBL] [Abstract][Full Text] [Related]
18. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer.
Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Seo SP; Kang HW; Kim WT; Lee JY; Ryu DH; Choi JW; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2019 Jun; 17(3):e704-e711. PubMed ID: 31088707
[TBL] [Abstract][Full Text] [Related]
19. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
